Kura Oncology Dirección
Dirección controles de criterios 4/4
El CEO de Kura Oncology's es Troy Wilson , nombrado en Mar 2015, tiene una permanencia de 9.25 años. compensación anual total es $5.25M, compuesta por 12.3% salario y 87.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.76% de las acciones de la empresa, por valor de $12.00M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 8.7 años, respectivamente.
Información clave
Troy Wilson
Chief Executive Officer (CEO)
US$5.3m
Compensación total
| Porcentaje del salario del CEO | 12.3% |
| Permanencia del CEO | 9.3yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 3.5yrs |
| Promedio de permanencia en la Junta Directiva | 8.7yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
May 08
Kura Oncology: Balancing Act Of Promise And Pragmatism
May 07Kura Oncology: Ziftomenib's Path To AML Market Widens
Jan 31Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price
Jan 25Is Kura Oncology (NASDAQ:KURA) A Risky Investment?
Aug 14Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?
Apr 04Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?
Jan 31Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans
Oct 10Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating
Jul 13We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth
Jun 26We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Nov 23We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate
Aug 09Kura Oncology Investor Presentation - Slideshow
May 08What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?
Dec 14
Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
Dec 10Kura Oncology (KURA) Presents At ASH Virtual Investor Event
Dec 08Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate
Dec 07Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow
Nov 17Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$5m | US$646k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$143m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$137m |
| Dec 31 2022 | US$5m | US$621k | -US$136m |
| Sep 30 2022 | n/a | n/a | -US$135m |
| Jun 30 2022 | n/a | n/a | -US$133m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$9m | US$600k | -US$130m |
| Sep 30 2021 | n/a | n/a | -US$124m |
| Jun 30 2021 | n/a | n/a | -US$114m |
| Mar 31 2021 | n/a | n/a | -US$101m |
| Dec 31 2020 | US$4m | US$573k | -US$90m |
| Sep 30 2020 | n/a | n/a | -US$81m |
| Jun 30 2020 | n/a | n/a | -US$74m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$3m | US$542k | -US$63m |
| Sep 30 2019 | n/a | n/a | -US$61m |
| Jun 30 2019 | n/a | n/a | -US$60m |
| Mar 31 2019 | n/a | n/a | -US$60m |
| Dec 31 2018 | US$5m | US$526k | -US$60m |
| Sep 30 2018 | n/a | n/a | -US$55m |
| Jun 30 2018 | n/a | n/a | -US$49m |
| Mar 31 2018 | n/a | n/a | -US$43m |
| Dec 31 2017 | US$2m | US$472k | -US$35m |
Compensación vs. Mercado: La compensación total ($USD5.25M) de Troy está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.66M).
Compensación vs. Ingresos: La compensación de Troy ha sido consistente con los resultados de la empresa en el último año.
CEO
Troy Wilson (55 yo)
9.3yrs
Permanencia
US$5,251,407
Compensación
Dr. Troy Edward Wilson, Ph D., J.D., is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since February 2019 until January 2021 and serves as its Independent Chairman of the Board...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 9.3yrs | US$5.25m | 0.76% $ 11.9m | |
| Chief Operating Officer | 4.8yrs | US$2.16m | 0.014% $ 219.3k | |
| Chief Legal Officer & Corporate Secretary | 2.7yrs | US$1.98m | 0.0071% $ 110.9k | |
| Chief Medical Officer | 3.8yrs | US$2.47m | 0.0040% $ 62.3k | |
| Senior Vice President of Finance & Accounting | 2.3yrs | sin datos | 0.016% $ 244.5k | |
| Executive Vice President of Investor Relations & Corporate Communications | 6.7yrs | sin datos | sin datos | |
| Senior Vice President of Manufacturing & Supply Chain | 4.4yrs | sin datos | sin datos | |
| VP and Global Head of Program Leadership & Project Management | 3.3yrs | sin datos | sin datos | |
| Executive Vice President of Clinical Development | 2.3yrs | sin datos | sin datos | |
| Chief Commercial Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Translational Research | no data | sin datos | sin datos |
3.5yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KURA se considera experimentado (3.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 9.3yrs | US$5.25m | 0.76% $ 11.9m | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Independent Director | 8.7yrs | US$275.69k | 0% $ 0 | |
| Independent Director | 5.6yrs | US$279.80k | 0% $ 0 | |
| Lead Independent Director | 9.2yrs | US$300.54k | 0.031% $ 493.8k | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Chairman of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Clinical Advisor | no data | sin datos | sin datos | |
| Independent Director | 3yrs | US$279.05k | 0% $ 0 |
8.7yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de KURA se considera experimentada (8.7 años de antigüedad promedio).